ann out re immunoxel, page-36

Think your missing the big picture. With regard to Immunoexcel, it is only through Peter BOONEN and because of his previous directorship with Zodiac Capital, and previous links and associations with Immunitor and Ekomed, that STI have the opportunity to develop and market Immunoxel at all.

The right to develop Immunoxel , basically in the western world including Australia and some European countries (but excluding Ukrane,Russia, Africa and some other countries), was given in the first place to Zodiac Capital. BOONEN then being a director of Zodiac Capital and having earlier connections to Immuitor/Ekomed, the original developers of Immunoxel. BOONEN, then also being CEO of STI, passed on that right to develop and market it to STI in partnership with Zodiac Capital, because he was a director of Zodiac Capital. If you recall last year BOONEN tried to introduce it direct along with other bi-botanical products in an on line sales platform in the US in Jabnuary, 2010, but was thwarted by the US authorities changing their regulatory approval process for bio-botanicals. It was discussed back then that it could take years to get approvals for it in the US and or Australia.

Also bear in mind that like most other products STI was then being attacked because of BOONEN?s alleged history, SP dived to current low levels and STI lacked the capital to develop all the products including Immunoxel, with emphasis remaining on spending to maintain the Canadian factory and get it up and running, along with Telemedcare, HDA device, with incoming Jeremy COX ex Novartis and Pfitzner CEO/problem solver to seal the deals, plus getting leg in door to Australian Pharmacies and establishing a sales force re same and subsequently other pharmacy products, face cream, associations with kidney Foundation, Kidney vital, 3m brand products etc. No where near enough money for them, let alone early development of Immunoexcel, hence pretty well left in abeyance and may have dropped the ball keeping track of developments in that area.

Then earlier this year, Ekomed (over which BOONEN has no control), give their remaining rights to Russia, Africa and ?some other countries?), to Immune Network to develop and market, and around march this year Immune Network exposed their V5 tableted form of Immunoxel. And yes, BOONEN is connected with Immune Network and BAIN), as he is with several other companies, so what.

What many are still not understanding is, if it were not for BOONEN and his connections to Zodiac and Ekomed and Immunator and Immune Networks, STI would not have these other products to work with, including Immunxel, Kidney vital and another 24 to come. On top of there we may well not have been the pharmaceutical company in Canada, the sales team and products to Australian pharmacies, and products, 3m contracts, Kidney Foundation connections, Honeydrop connections, a damn good foothold for development and sales of HAD device, Telemedcare and future products, already vitually 3 companies in one with an excellent team of highly creditialed and experienced ?Team? to make it all happen, along with the new as long as with and exceptional in fact STI could still be just baby wipes. And regardless of any old shady history, that is the difference today, namely the ?Team? and the rang of potentially high end, high earning products, STI now can develop and market as long as it can stay financial enough to do so, that is the only potential stumbling block which is now being reduced with factory contracts and pharmacy sales, but still a long expensive road to travel.

So if BOONEN, and/or BAIN, and./or Immune Networks new board member Dr. Aldar BOURINBAIAR, appointed about a month before Immune Network announced their V5, and/or STI?s Dr Michael TOUNGE, (both of the later involved in the original development of Immunoxel with Immunator/Ekomed), had any influence over Immune Networks getting the other rights and subsequently the STI/Immune network share agreement re same, neither having access to huge amounts of capital, then I say well done, because we now have potential Global access rights to develop and market all Immunoxel products (apologies still probably not Ukraine/Russia likely still Ekomed?s), and the profit from this. We didn?t have all that before ? Smart man/men I say and because of it we all stand to profit ?

Re dilution and profits, re my post about 3 posts ago (you need the last/corrected one on the share deal 30/511), STI get 20 million shares in Immune Networks on current value worth about $430,240.00, for STI issuing 12.5 Mil Shares to Immune Network on current value about $53,437.50 and Zodiac Capital issuing 33,333 shares to Immune Network on current value another of my recent posts That means STI (and you/us shareholders) get over $333,469 more in share value than Immune Networks get, for STI to continue to develop their own Immunoxel product, whilst Immune networks continues trailing their advanced tableted form V5 and its derivatives, and STI (and therefore you, STI?s shareholders), get access to profits from either or both products, which if continue to produce the extremely promising results thus far obtained will result in huge profits to both companies. And STI got over $330,000 value in share trade to secure the deal. Not too bad in my book for access to potential global sales ?

This post is long enough so not going to repeat but you need to join all the dots, some of my recent and then not so recent posts including those about the "team" and the "Products" may help, and if you have the time and want to bore yourself silly yet again, most of these facts can be found in STI releases from 2009 to current and on the Zodiac, Bloomberg and various other share news sights.

As a result I believe it's still just getting better and better, if we survive the fiancial side, the upside is huge.